23 February 2026 - Eli Lilly today announced the US FDA approved a label expansion for Zepbound (tirzepatide) to include the four-dose single-patient use KwikPen that delivers a full month of treatment in one device. 

With the Zepbound KwikPen, Lilly is expanding choice and helping ensure patients and health care providers can select the option that best fits individual needs, preferences, and circumstances. Patients, with a valid prescription, opting for self-pay through LillyDirect, can receive all doses of Zepbound in a KwikPen or single dose vial, starting at $299/month for the 2.5 mg dose.

Read Eli Lilly press release